Latham & Watkins advised 4D Molecular Therapeutics, while Cooley advised the underwriters for the offering.4D Molecular Therapeutics, Inc. has announced that it priced an upsized underwritten…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
